Effects of intravenous nicorandil on the mid-term prognosis of patients with acute heart failure syndrome

Circulation Journal

Volumn 76, Issue 5, 2012, Pages 1169-1176

  Ishihara, Shiro ^a   Koga, Tokushi ^a   Kaseda, Shigeru ^a   Nyuta, Eiji ^a   Haga, Yoshie ^a   Fujishima, Shinichiro ^a   Ishitsuka, Takao ^a   Sadoshima, Seizo ^a  

^a STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

Author keywords

Acute heart failure syndrome; Nicorandil; Prognosis

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR ALPHA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; HEMOGLOBIN; LOOP DIURETIC AGENT; NICORANDIL;

ACUTE HEART FAILURE; AGE; AGED; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART RATE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROGNOSIS; PULSE PRESSURE; RETROSPECTIVE STUDY; SURVIVAL; SYSTOLIC BLOOD PRESSURE;

ACUTE DISEASE; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NICORANDIL; RETROSPECTIVE STUDIES; SURVIVAL RATE; SYNDROME;

EID: 84860184800     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1110     Document Type: Article

References (31)

1. Zannad F, Adamopoulos C, Mebazaa A, Gheorghiade M. The challenge of acute decompensated heart failure. Heart Fail Rev 2006; 11: 135-139.
2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
3. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 119: 1977-2016.
4. Mebazaa A, Gheorghiade M, Piña IL, Harjola VP, Hollenberg SM, Follath F, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 2008; 36: S129-S139.
5. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989; 63: 18J-24J.
6. Minami Y, Nagashima M, Kajimoto K, Shiga T, Hagiwara N. Acute efficacy and safety of intravenous administration of nicorandil in patients with acute heart failure syndromes: Usefulness of noninvasive echocar diographic hemodynamic evaluation. J Cardiovasc Pharmacol 2009; 54: 335-340.
7. Tanaka K, Kato K, Takano T, Katagiri T, Asanoi H, Nejima J, et al. Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure. J Cardiol 2010; 56: 291-299.
8. + channel opener nicorandil. Eur Heart J 2003; 24: 1296-1303.
9. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33: 654-660.
10. Iwakura K, Ito H, Okamura A, Koyama Y, Date M, Higuchi Y, et al. Nicorandil treatment in patients with acute myocardial infarction: A meta-analysis. Circ J 2009; 73: 925-931.
11. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005; 112: 1284-1288.
12. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
13. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, et al. In-hospital mortality in patients with acute compensated heart failure requiring intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure Registry (ADHERE). J Am Coll Cardiol 2005; 46: 57-64.
14. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002; 39: 798-803.
15. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 2005; 293: 1900-1905.
16. Kamijo T, Kamei K, Sugo I, Kamiyama T, Sudo H, Ohba Y. Hemodynamic and hormonal responses to nicorandil in a canine model of acute ischemic heart failure: A comparison with cromakalim and nitroglycerin. J Cardiovasc Pharmacol 1999; 33: 93-101.
17. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-1491.
18. Giles TD, Pina IL, Quiroz AC, Roffidal L, Zaleski R, Porter RS, et al. Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in human. J Cardiovasc Pharmacol 1992; 20: 572-578.
19. Shirakabe A, Hata N, Yokoyama S, Shinada T, Kobayashi N, Asai K, et al. Efficacy and safety of nicorandil therapy in patients with acute heart failure. J Cardiol 2010; 56: 339-347.
20. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989; 261: 884-888.
21. Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 2009; 53: 2343-2348.
22. Pang PS, Komajda M, Gheorghiade M. The current and future management of acute heart failure syndromes. Eur Heart J 2010; 31: 784-793.
23. Pecini R, Møller DV, Torp-Pedersen C, Hassager C, Køber L. Heart failure etiology impacts survival of patients with heart failure. Int J Cardiol 2011; 149: 211-215.
24. Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, et al. Acute decompensated heart failure syndromes (ATTEND) registry: A prospective observational multicenter cohort study: Rationale, design, and preliminary data. Am Heart J 2010; 159: 949-955. e1.
25. Akai K, Wang Y, Sato K, Sekiguchi N, Sugimura A, Kumagai T, et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: Its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol 1995; 26: 541-547.
26. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Shimizu M, Nishii T, et al. Additive effects of nicorandil on coronary blood flow during continuous administration of nitroglycerin. J Am Coll Cardiol 2001; 37: 719-725.
27. Ito N, Nanto S, Doi Y, Sawano H, Masuda D, Yamashita S, et al. High index of microcirculatory index level after successful primary percutaneous coronary intervention can be improved by intracoronary administration of nicorandil. Circ J 2010; 74: 909-915.
28. Horinaka S, Yabe A, Yagi H, Ishimitsu T, Yamazaki T, Suzuki S, et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J 2010; 74: 503-509.
29. Larsen AI, Gøransson L, Aarsland T, Tamby JF, Dickstein K. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J 1997; 134: 435-441.
30. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: Insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2008; 52: 347-356.
31. Barsheshet A, Shotan A, Cohen E, Garty M, Goldenberg I, Sandach A, et al. Predictors of long-term (4-year) mortality in elderly and young patients with acute heart failure. Eur J Heart Fail 2010; 12: 833-840.